AngioDynamics (ANGO) investor relations material

Executive summary

• Achieved strong and accelerated revenue growth in fiscal 2026, with Med Tech segment growing 18.4% and comprising 47% of total revenue, up from 22% in 2020, supported by commercial execution and innovation.

• Consistent execution led to increased profitability and positive adjusted EBITDA, despite absorbing new tariffs and investing in innovation.

• Leadership transition underway, with CEO set to retire and a search for a successor in progress.

Financial highlights

• Q4 revenue increased 8% year-over-year to $86.6 million; Med Tech revenue up 16.7% to $41.8 million; Med Device revenue up 1.1% to $44.8 million.

• Full-year revenue rose 9.4% to $320.2 million; Med Tech revenue up 18.4% to $150 million; Med Device revenue up 2.5% to $170.2 million.

• Gross margin for Q4 was 54%, up 130 bps; full-year gross margin was 54.6%, up 70 bps despite tariff headwinds.

• Adjusted EBITDA for the year was $13.2 million, up from $7.6 million in 2025; Q4 adjusted EBITDA was $3.3 million.

• Ended the year with $53.9 million in cash and a debt-free balance sheet.

Outlook and guidance

• Fiscal 2027 net sales expected between $336 million and $341 million, representing 5%-7% growth.

• Med Tech net sales projected to grow 12%-15%; Med Device sales expected to be flat.

• Gross margin guidance of 54%-55%; adjusted EBITDA of $13-$16 million; adjusted loss per share of $0.29-$0.24.

• Tariff impact expected to be similar to 2026.